Hashimoto Koshi, Matsumoto Shunichi, Yamada Masanobu, Satoh Teturou, Mori Masatomo
Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, 3-39-22 Showa-machi Maebashi, Gunma, Japan 371-8511.
Endocrinology. 2007 Oct;148(10):4667-75. doi: 10.1210/en.2007-0150. Epub 2007 Jul 12.
The nuclear oxysterol receptors, liver X receptors (LXRs), and thyroid hormone receptors (TRs) cross talk mutually in many aspects of transcription, sharing the same DNA binding site (direct repeat-4) with identical geometry and polarity. In the current study, we demonstrated that thyroid hormone (T(3)) up-regulated mouse LXR-alpha, but not LXR-beta, mRNA expression in the liver and that cholesterol administration did not affect the LXR-alpha mRNA levels. Recently, several groups have reported that human LXR-alpha autoregulates its own gene promoter through binding to the LXR response element. Therefore, we examined whether TRs regulate the mouse LXR-alpha gene promoter activity. Luciferase assays showed that TR-beta1 positively regulated the mouse LXR-alpha gene transcription. Analysis of serial deletion mutants of the promoter demonstrated that the positive regulation by TR-beta1 was not observed in the -1240/+30-bp construct. EMSA(s) demonstrated that TR-beta1 or retinoid X receptor-alpha did not bind to the region from -1300 to -1240 bp (site A), whereas chromatin-immunoprecipitation assays revealed that TR-beta1 and retinoid X receptor-alpha were recruited to the site A, indicating the presence of intermediating protein between the nuclear receptors and DNA site. We also showed that human LXR-alpha gene expression and promoter activities were up-regulated by thyroid hormone. These data suggest that LXR-alpha mRNA expression is positively regulated by TR-beta1 and thyroid hormone at the transcriptional level in mammals. This novel insight that thyroid hormone regulates LXR-alpha mRNA levels and promoter activity should shed light on a cross talk between LXR-alpha and TR-beta1 as a new therapeutic target against dyslipidemia and atherosclerosis.
核氧甾醇受体、肝脏X受体(LXRs)和甲状腺激素受体(TRs)在转录的许多方面相互作用,它们共享具有相同几何形状和极性的相同DNA结合位点(直接重复序列-4)。在本研究中,我们证明甲状腺激素(T3)上调肝脏中小鼠LXR-α而非LXR-β的mRNA表达,并且给予胆固醇不影响LXR-α的mRNA水平。最近,几个研究小组报道人类LXR-α通过与LXR反应元件结合来自动调节其自身基因启动子。因此,我们研究了TRs是否调节小鼠LXR-α基因启动子活性。荧光素酶测定表明TR-β1正向调节小鼠LXR-α基因转录。对启动子的系列缺失突变体分析表明,在-1240/+30-bp构建体中未观察到TR-β1的正向调节作用。电泳迁移率变动分析(EMSA)表明TR-β1或视黄酸X受体-α不与-1300至-1240 bp区域(位点A)结合,而染色质免疫沉淀测定表明TR-β1和视黄酸X受体-α被募集到位点A,这表明在核受体和DNA位点之间存在中间蛋白。我们还表明甲状腺激素上调人类LXR-α基因表达和启动子活性。这些数据表明,在哺乳动物中,LXR-α mRNA表达在转录水平上受到TR-β1和甲状腺激素的正向调节。甲状腺激素调节LXR-α mRNA水平和启动子活性这一新颖见解,应为LXR-α与TR-β1之间的相互作用作为抗血脂异常和动脉粥样硬化的新治疗靶点提供线索。